To test the hypothesis in hippocampus, we infused 0.3, 1, and 3 mM NMDA at 2 µl/min over 60 min via 45 an implanted microdialysis probe. The dialysate samples collected every 20 minutes during the infusion 46
were analyzed for focal changes in extracellular glutamate release and quantified by high-performance 47 liquid chromatography (HPLC). Microdialysis at 0.3, 1, and 3 mM showed dose-dependent increases of 48 glutamate (39%, 200% and 670 %, respectively) in hippocampus. We recorded dose-dependent increases 49 of the PA signal with 0.3 and 3 mM NMDA infusion as predicted. Quantitative EEG at 3 mM NMDA 50 infusion confirmed induction of focal seizure activity. Transcranial PA VSD imaging provided up to 51 301±42% of fractional neural activity index change measured at the contralateral side of the microdialysis 52 probe with 3 mM NMDA infusion, compared to the decrease of -24±34% with 0.3 mM NMDA 53
infusion. This graded response suggests dentate gyrus (DG) gatekeeping in hippocampus. 54
In sensorimotor cortex, intracerebral infusion of NMDA at 0.3 mM elicited the predicted increase of 55 glutamate release, with a decrease of qEEG spectral power. . Transcranial PA VSD imaging had -56 13±37% of fractional neural activity index change during the 20 min of 0.3 mM NMDA infusion, 57 consistent with surround suppression of depolarization as shown by qEEG of motor cortex. 58
We conclude that transcranial PA VSD imaging distinguished relatively greater cortical inhibition and 59 threshold-level hippocampal focal seizure activity that both correlated with activities reported by qEEG 60 signals. The results show this emerging technology to be an innovative and significant advance of 61 functional neuroimaging. 62 63
Introduction 64
Whereas electrophysiological and invasive neurochemical techniques have been valuable in assessing 65 activity within specific neural circuits in brain, there is a distinct need for a noninvasive means to image 66 real-time regional functional activity in vivo. In particular, motor cortex and hippocampus are of interest, 67 as they present distinct circuits with clear electrophysiological modulation of excitatory 68 neurotransmission. It is long known that neocortical structures such as the motor cortex exhibit both 69 excitatory and feedforward as well as feedback inhibitory mechanisms driven by NMDA that limit neural 70 activity and modulate oscillatory firing. The focal application of low doses of NMDA is known to 71 activate spreading cortical depression that depends on NMDA receptors (Hansen et Microdialysis. On the day of the study the rats were weighed and anesthetized with urethane 137 (1.2mg/kg,). Urethane was given incrementally with alternating ip and sc dosing. Three (3) ml of isotonic 138 saline was given sc on each side of the body to keep the animal hydrated during the experimental 139 procedure. Body temperature was maintained until animal was fully anesthetized and ready for surgery.
140
For PA and EEG studies, an iv catheter was inserted into a tail vein prior to surgery for dye 141 administration during the studies. Once a stable plane of anesthesia was established, hair was shaved 142 from the scalp of each rat for improved optical/acoustic coupling for transcranial PA recording. The rat 143 was placed into a stereotaxic device (Stoeling Co. Wood Dale, IL). This fixation procedure was required 144 to prevent any unpredictable movement during PA or EEG recording of neural activities. A CMA12 145 microdialysis probe (Harvard Apparatus, Holliston, MA, USA) was implanted into either the right lobe 146 of the frontal cortex (stereotaxic coordinates: 1.5 mm lateral and 3.2 mm anterior to bregma, and 3 mm 147 below the surface of the dura) or the CA3 region of the right hippocampus (stereotaxic coordinates: 148 3 mm lateral and 3.8 mm posterior to bregma, and 3.6 mm below the surface of the dura) (Paxinos and 149
Watson, 2014). The probe active exchange surface was 2 × 0.5 mm. For EEG and PA experiments, 150 probes were secured to the skull using dental acrylic cement. 151
In vivo microdialysis. In vivo microdialysis sampling was carried out as previously described ( infusion. Following these samples, NMDA was infused into the brain directly through the dialysis probe 160 with the same pump parameters as used for the baseline samples. Dialysate samples were assayed for 161 glutamate by a two-step process using HPLC-ECD on an Eicom HTEC-500 system (EICOM, San 162
Diego, CA, USA). After passing the samples through a separation column, they were processed via a 163 column containing immobilized L-glutamate oxidase enzyme, resulting in the release of hydrogen 164 peroxide. The hydrogen peroxide concentration was then determined using a platinum working 165 electrode. Chromatographic data were acquired online and exported to an Envision software system 166 (EICOM, San Diego, CA, USA) for peak amplification, integration, and analysis. 167
Quantitative EEG. All EEG recordings utilized a three-electrode paradigm: 1 recording, 1 reference 168 (aligned to the site of activation) and 1 ground over the rostrum. The electrodes (IVES EEG; Model # 169 SWE-L25 -IVES EEG solutions, MA, USA) were fixed with minimal cyanoacrylate adhesive 170 (KrazyGlue), similar to previous protocols (Airan et al., 2017) . Data acquisition was performed using 171
Sirenia software (Pinnacle Technologies Inc., Kansas, USA) with synchronous video capture. Data 172 acquisition had a 14-bit resolution, 400Hz sampling rate, and a band pass filter between 0.5 Hz and 60 173
Hz. The acquisition files were stored in an .EDF format and scored manually, using real time annotations 174 from the experiments. EEG power for 2-second epochs was done using an automated fast Fourier 175 transformation module in Sirenia software (Kang et al., 2018) . 176
Photoacoustic imaging. We used real-time PA data acquisition to record electrophysiological neural 177 activities in vivo: an ultrasound research system consisted of an ultrasound linear array transducer (L14-178 5/38) connected to a real-time data acquisition system (SonixDAQ, Ultrasonix Medical Corp., Canada).
179
The center frequency of the transducer was 7.1 MHz to obtain good sensing depth for neural activities in 180 deep brain tissue. To induce the PA signals, pulsed laser light was generated by a second-harmonic (532 181 nm) Nd:YAG laser pumping an optical parametric oscillator (OPO) system (Phocus Inline, Opotek Inc., 182 USA), providing 690-900 nm of tunable wavelength range and 20 Hz of the maximum pulse repetition 183 frequency. A bifurcated fiber optic bundle, each 40 mm long and 0.88 mm wide, was used for laser pulse 184 delivery. The PA probe was posed between the outlets of the bifurcated fiber optic bundles using a 185 customized, 3-D printed shell for evenly distributed laser energy density in the lateral direction on rat 186 scalp surface. The alignment of outlets was focused specifically at 20 mm depth. The PA probe was 187 positioned in the sagittal plane to cover the barrel cortex and hippocampus at the same time. Lateral 188 position of the probe was at the contra-lateral side of microdialysis probe: 1.5 mm for motor cortex 189 recording; 3 mm for hippocampus. The distance between the PA probe and the rat skin surface was 20 190 mm filled with acoustic gel, and the resultant energy density was at ~5 mJ/cm 2 , which is far below the 191 maximum permissible exposure (MPE) of skin to laser radiation by the ANSI safety standards. (Anon, 192 1975) A wavelength of 790 nm was used, at which sufficient absorbance can be obtained by the near-193 infrared VSD, i.e., IR780 perchlorate. Also, probing at the wavelength prevented the undesired time-194 variant change of oxygen saturation, being at the isosbestic point of Hb and HbO2 absorption spectra. 195 Fig. 4b presents a representative sagittal cross-sectional PA image of a rat brain. The brain outline was 196 drawn based on the rat brain atlas (Paxinos and Watson, 2014) . Detailed information of neural activity 197 reconstruction using normalized time-frequency analysis can be found in our previous publication (Kang 198 et al., 2017) . 199
In vivo experimental protocol. The in vivo protocols were designed for simultaneous multi-modal 200 sensing of the neural activity at motor cortex and hippocampus: microdialysis-qEEG and microdialysis-201
PA imaging. Figure 2 shows a detailed schematic protocol for each group representing the response to 202 the administration of NMDA, Lexiscan and VSD (i.e., IR780 perchlorate). PA and qEEG data 203 acquisition was performed for 40 min to correlate with three microdialysis samples collected at 20-min 204 intervals. VSD and Lexiscan followed the data acquisition sequence with 3-min delay, thereby 5 min of 205 baseline phase was guaranteed for neural activity index reconstruction in PA imaging before starting 206 NMDA infusion. The dosing protocol for Lexiscan and VSD administration was as follows: through an 207 iv tail vein catheter, 150 µl of Lexiscan (0.4mg/5ml) was injected, followed by 200 µl of VSD at 2mg/ml 208 concentration, flushed immediately with 150 µl of 0.9% isotonic saline. The EEG signal at motor cortex 209 was recorded an identical preparation procedure as the PA imaging, including animal preparation and 210 administration of IR780, Lexiscan and experimental duration time for all recordings. 211 Brain histology. Rats used for the above protocol were sacrificed, and whole brains immediately 212 harvested and placed in 10% formalin. All brains were allowed to fix in fresh 10% formalin for at least 213 48 hours with gentle agitation on a conical rotator. Subsequently, the brains were processed through a 214 series of sucrose gradients (15%, 20%, 30% for 12-24 hours each) for cryoprotection. Brains were 215 sectioned frozen at 300 µm thickness. Tissue sections were mounted on slides in ProLong Diamond 216
Anti-face mountant. Slides with sections were imaged using an Olympus OM-D E-M5 Mark II for bright 217 field image and using LI-COR Odyssey for fluorescence visualization. 218 219
Results

220
NMDA-evoked glutamatergic neurotransmission. Intracortical and intrahipocampal infusion of 221
NMDA diluted into artificial cerebrospinal fluid at the required concentrations, was infused through the 222 microdialysis probe. Concentrations of glutamate release in the dialysate were calculated from values of 223 three baseline samples collected at 20 minutes intervals before NMDA infusion. During infusion, 224 samples continued to be collected every 20 minutes for the remainder of the study. Glutamate release 225
were calculated as a % of basal values. Figure 3 shows the effect of NMDA infusion on 226 glutamate release in the motor cortex and the hippocampus of anesthetized rats. Figure 3a shows that 227 infusion of 0.3 mM NMDA into the motor cortex caused a roughly 60 % increase in glutamate levels as 228 compared to baseline samples. The increase occurred in the first 20-minute sample collection 229 period following the onset of NMDA infusion, and was sustained for the full infusion period. Figure 3b  230 demonstrates the dose-related response of NMDA infusion at 0.3, 1.0, and 3.0 mM into the 231 hippocampus, where 0.3 mM NMDA caused a roughly 40% increase in glutamate levels that remained 232 elevated for the duration of the infusion; the 1.0-mM NMDA infusion appears to cause doubling of the 233 glutamate levels in the hippocampus compared to baseline. This increase observed at the 1.0-mM 234 remained elevated through to the end of the NMDA infusion. However, at 3.0-mM, the NMDA infusion 235 raised the glutamate level roughly 6-fold, above baseline level, which peaked during the second 20-236 minute sampling period, after which it began a steady decline to the termination of the infusion. The 237 increase in glutamate release seen in microdialysis in the motor cortex did not correlates with measures 238 of VSD imaging with PA, but good correlations were seen in the hippocampus. Interestingly, qEEG also 239 revealed no seizure activity with infusion into motor cortex at the 0.3-mM concentration, but elicited a 240 strong seizure response in hippocampus with infusion of 3-mM NMDA in the time period that 241 coincided with peak glutamate activity in the dialysate. 242 EEG of electrophysiological activity in motor cortex and hippocampus. We used qEEG to 243 investigate whether the NMDA-induced glutamate release seen with microdialysis activates circuits in 244 motor cortex and hippocampus. In order to establish circuit activity differences of reactivity to the 245 specific focal stimulations, recordings of qEEG were used to interpret PA values acquired with the same 246 protocols to establish spatial and temporal relationship. The temporal specificity of qEEG expressed 247 circuit responses in realtime, before and after focal NMDA infusion. However, qEEG lacks spatial 248 resolution, and records cannot be obtained from deep brain structures with leads placed on brain or skull 249 surfaces. Therefore, we opted not to place in-depth electrodes, in order to maintain the experiments as 250 possible. We made the stimulation focal, according to the previous proof-of-concept results by PA 251 detection onset of generalized seizures through an intact skull (Kang et al., 2017) . 252
When 0.3-3 mM NMDA was delivered to distinct motor cortex and hippocampal circuits by 253 microdialysis probe (Figure 1a ) (Paxinos and Watson, 2014) , results showed that NMDA infusion of 0.3 254 mM NMDA at the M2 coordinates of the motor cortex caused the expected rise of local glutamate 255 release measured in microdialysis (Figure 3 ) that had an effect on qEEG spectral power; specifically in 256 the gamma frequency (Figure 4-a2) . The resulting qEEG suppression seem to indicate focal glutamate-257 induced activation of surround inhibition; becoming more prominent over the duration of the infusion 258 (Figure 4-b2) . In contrast, a 3 mM infusion into the hippocampus immediately resulted in increased 259 bursts of gamma power in the EEG, followed by a focal seizure (Figure 4 and S1). Unlike the cortical 260 circuit that showed increasing EEG suppression over time, the hippocampal circuit continued to exhibit 261 short epileptiform discharges throughout the NMDA infusion period (Figure S1b V), indicating 262 continued disruption of the DG gating during the entire duration of the NMDA infusion. 263
Transcranial PA imaging. Transcranial PA neuroimaging of distinct neural mechanisms in motor 264 cortex and hippocampus was performed at the contralateral position of microdialysis probe (Figure 5a ).
265
The PA sagittal planes obtained at 790 nm presented a sufficient sensitivity at the depths of interest in rat 266 forebrain: 2.5 mm and 3.6 mm for motor cortex and hippocampus, respectively (Figure 5b ). The motor 267 cortex imaging plane presented high intensity at the superior sagittal sinus at superficial depth, and the 268 morphological boundary of brain tissue could be distinguished based on the rat brain atlas and PA signal 269 distribution representing both blood and VSD in brains. The sagittal PA imaging plane of hippocampus 270 also revealed the cross-sections of transverse sinus and inferior cerebral vein in the superficial depth 271
range, but it also shows sufficient sensitivity at the depth of hippocampus. From the regions-of-interest 272 (ROIs) indicated with solid white box, time-averaged neural activity index was reconstructed pixel-by-273 pixel for baseline (5 -10 min) followed by the results for time bins in 10 min interval: 10 -20 min, 20 -274 30 min, and 30 -40 min ( Figure 5c ). As a result, the substantial amount of circuit dynamics was detected 275 at hippocampus with 3 mM NMDA infusion, while demonstrating negligible change at motor cortex as 276 predicted by their distinct mechanisms. Otherwise, the hippocampus with 0.3 mM NMDA infusion did 277 not present any significant change, which implies a failure to overcome high activation threshold of DG 278 gatekeeping with 0.3 mM NMDA infusion. This interpretation is supported with the subtle change in 279 extracellular glutamate concentration shown with forward microdialysis (Figure 3b ) 280
To further characterize the PA VSD intensity change, the normalized neural activity index 281 sequence at the ROIs indicated by red dots was plotted as a function of the corresponding normalized 282 PA intensity (Figure 5d ). Note that the size of each ROI was 1 x 1 mm 2 , and the reference intensity was 283 obtained from the baseline phase: 5-10 min. In motor cortex, 0.3-mM NMDA infusion presented 284 complex suppression mechanism in the cortical region: The quantification of normalized neural activity 285 index presented 1.00 ± 0.36, 0.87 ± 0.37, and 1.19 ± 0.36 for baseline (5 -10 min), and first (10 -30 286 min) and second (30 -40 min) microdialysis phases (NMDA1 and NMDA2), respectively. This result 287 suggests the initial suppression at the first 20 min of NMDA infusion (i.e., -13 %), which is well 288 correlated to the electrophysiological validation in qEEG recording (Figure 4-a2) . On the other hand, 3-289 mM NMDA infusion at hippocampus yielded significant elevation of neural activity index as 290 corresponding PA intensity decreases: 1.00 ± 0.35 %, 1.55 ± 0.36 %, and 1.74 ± 0.33 % of normalized 291 neural activity indices for baseline, NMDA1, and NMDA2 phases, respectively. This validates the 292 proposed VSD mechanism which yields suppressive intensity to neuronal depolarization (Zhang et al., 293 2017). Otherwise, focal 0.3 mM NMDA infusion at hippocampus did not presented any statistically-294 significant circuit activity increase compared to the baseline neural activity index: 1.00 ± 0.31 %, 0.99 ± 295 0.41 %, and 0.76 ± 0.34 % of normalized neural activity indices for baseline, NMDA1, and NMDA2 296 phases, respectively. These results support our hypothesis that PA imaging can differentiate the DG 297 gating function at the hippocampus. In all, when tracing the change of circuit dynamics from the 298 baselines, the 3-mM NMDA infusion at hippocampus presented statistically significant difference 299 compared to those with 0.3 mM at both hippocampus and motor cortex (P < 0.0001). The VSD 300 mechanism suppressive to neuronal depolarization could be also confirmed with the temporal specificity 301 of PA neuroimaging. The successful extraction of neural activity index was also confirmed in Figure 5e  302 which presents the normalized neural activity index (top panel) and relative PA intensity to baseband 303 frequency component (bottom panel). As shown in the figure, NMDA inset produces suppressive PA 304 intensity around 1-dB from basal level, which is also synchronized to the focal seizure presented in 305 qEEG given by DG gating breakdown (Figure 4 -b2 and Figure S1 V), leading to 2.5-times instantaneous 306 increase of neural activity index for around 20 sec. Refer Figure S2 for the entire neural activity index and 307 PA intensity traces. 308 Figure 6 presents the normalized neural activity index as a function of extracellular glutamate 309 concentration at motor cortex and hippocampus. The motor cortex presents the comparable amount of 310 neural activity index with that of baseline phase at hippocampus (n = 1), but 3 mM NMDA infusion into 311 hippocampus produced exponential increase in neural activity index when the extracellular glutamate 312 concentration exceeds 6 µM in microdialysis sampling (n = 2). These results again confirm the DG 313 breakdown with specific glutamatergic potential threshold at neural circuitry. 314
Brain histology. Brain tissue was extracted after all in vivo experimental protocols. The brain was frozen-315
sectioned into 300-µm thickness slices and evaluated to confirm probe placement using the hemorrhage 316 caused by the microdialysis probe insertion for the NMDA infusion and collections as a marker. Figure 6  317 shows the bright-field images of the coronal plane of the motor cortex and hippocampus at 3.2 mm and 318 -3.8 mm from bregma, respectively. White arrows indicate the hemorrhage caused by the microdialysis 319 probe positioned at the following coordinates: bregma 3.2 mm, lateral 1.5 mm, depth 2.5 mm for motor 320 cortex; bregma -3.8 mm, lateral 3 mm, and depth 3.6 mm for hippocampus. The VSD staining of brain 321 tissue was confirmed with near-infrared fluorescence microscopy. Uniform VSD fluorescence was found 322 in the VSD perfusion group, while negative control (VSD -) presented negligible fluorescence emission 323 ( Figure S3 ), which confirms the results in our previous publication (Kang et al., 2017 dynamics that lead to the initiation of a focal seizure in the hippocampal circuit. (3) Transcranial PA 363 neuroimaging data successfully validated these EEG specific opposite circuit activity profiles for the 364 similar focal activation of NMDA receptors. No circuit activity was detected in the motor cortex on the 365 PA imaging despite an increase in focal glutamate levels recorded in the same rats. In contrast, the PA 366 signal yielded hot spots of neuronal activity following NMDA receptor activation in the hippocampus. 367
These results allow us to reassess the differential neural mechanisms modulating activity between 368 motor cortex and hippocampus as described in the Introduction: Strong local circuit inhibition has been 369 observed with transcranial PA neuroimaging and qEEG recording. Cortical inhibition may be due to 370 suppression of neuronal firing mediated by γ-amino butyric acid (GABA) receptors (Krnjević, 1997) 371 secondary to activation of GABAergic inhibitory interneurons by NMDA (Homayoun and Moghaddam, 372 2007). Slice electrophysiology in animal and human cortical tissue have revealed two main phases of 373 inhibition following stimulation; a "fast" phase mediated by ionotropic GABAA receptors and a "slow" 374 phase mediated by metabotropic GABAB receptors (Connors et al., 1988; McCormick, 1989) . Inhibition 375 provides the ability to locally modulate excitation as well as gate rhythmic activity, which is critical for 376
proper sensorimotor inputs and outputs. Such findings likely indicate a general pattern of cellular 377 connectivity intrinsic to cortical organization. 378
On the other hand, the hippocampal circuitry provides a second distinct circuit that contrasts 379 with that of the motor cortex to assess PA specificity, as it reveals the proportional excitation of 380 glutamatergic neurotransmission. The DG of the hippocampus is positioned as a gatekeeper for the 381 canonical trisynaptic circuit, regulating the vast cortical inputs that regulate the limbic system. 382
Characteristically, the DG displays a high activation threshold; a trait that is associated with executing 383 cognitive functions that require pattern separation and completion (Chawla et al., 2005) . The ability to 384 differentiate inputs, and diversify cognitive functions, is mediated by inhibition. Suitably, the DG is 385 profusely innervated with strong GABAergic inhibition (Szabo et al., 2017) . In diseases of 386 hyperexcitability, such as epilepsy, the DG can regulate pathological seizure activity from invading the 387 limbic system. This gating is evident in recordings from the DG during low frequency stimulation of the 388 perforant path fibers. The DG displays the ability to selectively filter low frequency stimulation by 389 subsequent activation of strong inhibitory post synaptic potentials (Andersen et al., 1966 ). Yet, longer or 390 higher frequency stimulations resulted in excitatory post synaptic potentials generated by the DG. This 391 disruption of DG gating has been clearly demonstrated by utilizing VSD imaging techniques, reinforcing 392 DG's role of gatekeeping (Ang et al., 2006) . The consequence of gatekeeping is that in epilepsy the DG 393 generates and propagates seizure activity. 394
Further investigations are required to advance our current perspectives available with tri-modal 395 sensing, including PA, qEEG, and microdialysis. Previous studies have shown that application of 396 glutamate to the hippocampal pyramidal neurons produces a fast-rising brief depolarization (Taube and 397 Schwartzkroin, 1987) . Therefore, the use of PA will enable us to more precisely assess glutamate and 398 GABA dynamics in order to formulate a more complete profile of circuit activation. Once homeostasis is 399 disrupted, neuronal activity is sensitive to changes both of excitatory and inhibitory mechanisms. 
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